Healthline lands Drugs.com ad sales deal

Share this article:
Healthline lands Drugs.com ad sales deal
Healthline lands Drugs.com ad sales deal
Healthline Networks has secured a deal with Drugs.com giving it exclusive rights to sell consumer ads on the site, which boasts 8.8 million unique visitors per month.

The agreement boosts Healthline's reach to nearly 55 million monthly uniques, said the San Francisco firm, or about half the monthly health information audience, per comScore stats.

“We wanted a partner that could help marketers take advantage of our critical position in the treatment consideration process,” said Drugs.com CEO Philip Thornton. “Healthline not only gives us a roster of strategic sellers with deep DTC experience but original, engaging content and visual learning solutions that can help marketers reach consumers and healthcare providers at a critical point of decision.”

Healthline, whose backers include Kaiser Permanente, Reed Elsevier, GE/NBC Peacock Fund and Aetna, offers search, advertising and content services through partnerships with 50-plus destination sites including web publishers, portals, search engines, employers and health plans.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...